Patents Assigned to OMNICYTE
  • Patent number: 11471518
    Abstract: The present disclosure relates to fusion proteins that comprise one or more modified alpha virus surface glycoproteins and one or more tumor specific antigens. Also disclosed are fusion proteins that comprise one or more modified alpha virus surface glycoproteins and one or more viral specific antigens. Also disclosed are fusion proteins that comprise one or more modified alpha virus surface glycoproteins. It also relates to methods to activate the immune system in cancer patients to infiltrate and kill tumor cells or cells infected with a latent virus. The present disclosure provides a platform technology that elicits a faster, broader and stronger immune response using the fusion proteins.
    Type: Grant
    Filed: April 9, 2020
    Date of Patent: October 18, 2022
    Assignee: OMNICYTE
    Inventors: Peter Leonardi, Elin Martina Pola, Jeffrey Babad
  • Patent number: 10660948
    Abstract: The present disclosure relates to fusion proteins that comprise one or more modified alpha virus surface glycoproteins and one or more tumor specific antigens. Also disclosed are fusion proteins that comprise one or more modified alpha virus surface glycoproteins and one or more viral specific antigens. Also disclosed are fusion proteins that comprise one or more modified alpha virus surface glycoproteins. It also relates to methods to activate the immune system in cancer patients to infiltrate and kill tumor cells or cells infected with a latent virus. The present disclosure provides a platform technology that elicits a faster, broader and stronger immune response using the fusion proteins.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: May 26, 2020
    Assignee: OMNICYTE
    Inventors: Peter Leonardi, Elin Martina Pola, Jeffrey Babad
  • Patent number: 9163234
    Abstract: The invention provides methods of culturing cells, particularly maintaining the differentiation potential of a population of cells with differentiation potential. The methods involve contacting cells with an inhibitor of miRNA-181a* and/or incubation in a serum-free medium. A serum-free medium is also provided. Also provided are progeny stem cells, methods of obtaining them, and uses thereof.
    Type: Grant
    Filed: October 6, 2011
    Date of Patent: October 20, 2015
    Assignee: Omnicyte Limited
    Inventor: Myrtle Gordon
  • Patent number: 8652846
    Abstract: The invention provides an apoptosis-modulating cell-free composition comprising conditioned extracellular medium of a stem cell and uses thereof, particularly therapeutic uses. Also provided is a method of obtaining such a composition and an in vitro method of modulating apoptosis.
    Type: Grant
    Filed: October 2, 2009
    Date of Patent: February 18, 2014
    Assignee: Omnicyte Limited
    Inventors: Nagy A. Habib, Myrtle Gordon
  • Publication number: 20110262392
    Abstract: The invention provides an apoptosis-modulating cell-free composition comprising conditioned extracellular medium of a stem cell and uses thereof, particularly therapeutic uses. Also provided is a method of obtaining such a composition and an in vitro method of modulating apoptosis.
    Type: Application
    Filed: October 2, 2009
    Publication date: October 27, 2011
    Applicant: OMNICYTE LIMITED
    Inventors: Nagy A. Habib, Myrtle Gordon
  • Publication number: 20090170193
    Abstract: The present invention relates to an isolated stem cell population wherein said stem cells are CD34+, capable of self regeneration, capable of differentiation into ectodermal, mesodermal and endodermal cells and capable of adhering to tissue-culture grade plastic as well as to methods of isolation of said cells, methods of culturing and differentiation thereof, the progeny of such methods of differentiation as well as uses, including therapeutic uses of the stem cells and their differentiated progeny.
    Type: Application
    Filed: March 3, 2009
    Publication date: July 2, 2009
    Applicant: OMNICYTE, LTD.
    Inventors: MYRTLE GORDON, NAGY HABIB